Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study-Reference-Cited by-同舟云学术

Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study

Published:2022-11-20 Issue:12 Volume:47 Page:2214-2222
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:Clinical Pharmacy Therapeu

Author:

Yang Na¹,Cao Bin²^ORCID

Affiliation:

1. Department of Nephrology Shangluo Central Hospital Shangluo China

2. Department of Nephrology Ankang Hospital of Traditional Chinese Medicine Ankang China

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13794

Reference27 articles.

1. Prevalence of chronic kidney disease in China: a cross-sectional survey

2. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis

3. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association

4. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions

5. Pharmacological urate-lowering approaches in chronic kidney disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials;Annals of Medicine;2024-05-13

2. Combination Treatment with Verinurad and Allopurinol in CKD;Journal of the American Society of Nephrology;2024-02-20

3. Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial;Therapeutics and Clinical Risk Management;2023-09

4. Salix subserrata Bark Extract-Loaded Chitosan Nanoparticles Attenuate Neurotoxicity Induced by Sodium Arsenate in Rats in Relation with HPLC–PDA-ESI–MS/MS Profile;AAPS PharmSciTech;2022-12-15